Aimmune Therapeutics
8000 Marina Boulevard
Suite 300
Brisbane
California
94005-1884
United States
About Aimmune Therapeutics
181 articles with Aimmune Therapeutics
-
In August, Nestlé gobbled up Aimmune in a $2.6 billion deal, and now the food allergy-focused company will serve as the point pharmaceutical business for Nestlé Health Science.
-
Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.
10/13/2020
Société des Produits Nestlé S.A. announced the results of the tender offer by its wholly-owned subsidiary, SPN MergerSub, Inc., to purchase all of the outstanding shares of common stock of Aimmune Therapeutics, Inc., other than any Shares held by Nestlé and its affiliates, for a price of USD 34.50 per Share
-
Nestlé commences tender offer for Aimmune Therapeutics, Inc.
9/14/2020
Société des Produits Nestlé S.A. announced that its wholly-owned subsidiary, SPN Merger Sub, Inc., is commencing a cash tender offer to purchase all of the outstanding shares of common stock of Aimmune Therapeutics, Inc. today for a price of USD 34.50 per share, net to the seller in cash, without interest and subject to any withholding taxes.
-
Aimmune Therapeutics Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science
8/31/2020
Sociétés des Produits Nestlé S.A., part of Nestlé Health Science, to acquire Aimmune for $34.50 per share in cash, representing a total equity value of $2.6 Billion and a 174% premium to Aimmune’s closing price on August 28, 2020
-
Jayson Dallas, president and chief executive officer of Aimmune, said the agreement with Nestlé recognizes the value of Aimmune’s longtime commitment to advancing therapies for food allergies.
-
Largest European Qualitative Study on Peanut Allergy Highlights Negative Impact of Avoidance and Fear of Accidental Peanut Allergy Reactions on Allergic Individuals and Their Caregivers
8/24/2020
Aimmune Therapeutics, Inc. announced that findings from APPEAL-2, the largest cross-sectional, pan-European, qualitative study to evaluate the psychosocial burden of living with peanut allergy, were published in Clinical & Experimental Allergy, the official journal of the British Society for Allergy & Clinical Immunology.
-
Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
8/7/2020
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 10:55 a.m. E.T. A live webcast of the presentation will be accessibl
-
Aimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides Recent Operational Highlights
7/30/2020
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2020.
-
Clinical Catch-Up: July 20-24
7/27/2020
It was a busy week for clinical trial news, with some very important early-stage trial data for various COVID-19 vaccines. Here’s a look. -
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights
7/23/2020
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on Thursday, July 30, 2020, at 4:30 p.m. ET to discuss its financial results for the quarter and six months ended June 30, 2020, and recent operational highlights. To access the live call by phone, dial (
-
Full Results of Aimmune’s Pivotal Phase 3 European ARTEMIS Trial of PALFORZIA® Published in The Lancet Child & Adolescent Health
7/21/2020
Full Results of Aimmune’s Pivotal Phase 3 European ARTEMIS Trial of PALFORZIA ® Published in The Lancet Child & Adolescent Health -- Peanut-Allergic Patients Treated with PALFORZIA Showed Desensitization to Peanut Protein with a Predictable Safety Profile at Nine Months – --Clinically Meaningful Improvements in Food Allergy Quality of Life Were Reported in all Age Groups -- BRISBANE, Calif.--( BUSINESS WIRE )-- Aimmune Therapeutics, Inc.
-
Aimmune Appoints Narinder Singh as Executive Vice President of Technical Operations
7/6/2020
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced the appointment of Narinder Singh as Executive Vice President, Technical Operations. Mr. Singh is a pr
-
Clinical Catch-Up: June 8-12
6/15/2020
It was a fairly busy week with clinical trial updates and announcements. Here’s a look. -
New Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued Immunomodulation in Patients with Peanut Allergy
6/8/2020
New Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued Immunomodulation in Patients with Peanut Allergy — After Two Years of Daily Treatment, More Than 80% of Patients Were Successfully Desensitized to 2000 mg Peanut Protein or Equivalent of About 14 Peanut Kernels— — Majority of Patients Treated Daily Also Reported Lower Rates of Adverse Events and Showed Higher Rates of Desensitization Compared to Non-Daily Dosing Groups —
-
New Data Show Patients Are Highly Satisfied With and Confident in the Efficacy of Daily Treatment With PALFORZIA™ After Nine Months
6/8/2020
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced new findings from the phase 3 ARTEMIS trial that show patients with peanut allergy aged 4 through 17 were highly satisfied after nine months of daily treatment with PALFORZIA™ [
-
Clinical Catch-Up: May 31-June 5
6/8/2020
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look. -
Aimmune Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
6/4/2020
June 4, 2020 12:00 UTC Aimmune Therapeutics to Present at the Goldman Sachs 41 st Annual Global Healthcare Conference
-
New PALFORZIA™ Data on Long-Term Safety, Efficacy and Immunomodulation and New Data on Patient Satisfaction with PALFORZIA Treatment to be Presented at EAACI 2020 Congress
6/1/2020
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for life-threatening food allergies, today announced it will present important new long-term safety, efficacy and immunological data from ARC004, an open-label, rollover study of the landmark pivotal PALISADE trial of PALFORZIA
-
Largest European Quantitative Study on Peanut Allergy Confirms Significant Need, Burden and Psychosocial Impact of Peanut Allergy on Allergic Individuals and their Caregivers
5/28/2020
Study highlights need to address varying levels of effective disease management, and the associated feelings of uncertainty, stress and isolation across eight European countries
-
Aimmune Therapeutics to Present at the RBC Capital Markets 2020 Global Healthcare Conference
5/12/2020
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its Chief Financial Officer, Eric Bjerkholt, will participate in a fireside chat at the RBC Capital Markets 2020 Global Healthcare Conference on Tuesday, May 19, 2020 at 4:50 p.m. E.T. A live webcast of the fireside chat will be accessi